| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06.23 | Horizon Therapeutics plc: Additional Data from Phase 4 TEPEZZA (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration | 894 | Business Wire | -- Data at Week 24 show 2.41 mm reduction in proptosis in patients treated with TEPEZZA compared with 0.92 mm in those who received placebo; 62% of TEPEZZA patients had clinically meaningful improvement... ► Artikel lesen | |
| 17.06.23 | Horizon Therapeutics plc: New Data from TEPEZZA (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks | 776 | Business Wire | Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a series of analyses demonstrating the risk of hearing-related events among people with Graves' disease and TED, including... ► Artikel lesen | |
| 17.06.23 | The Bank of London: Gründer der Bank of London Anthony Watson bei den ersten Ehrungen aus Anlass des Geburtstags Seiner Majestät König Charles III. zum CBE gekürt | 605 | Business Wire | Anthony Watson, Group Chief Executive und Gründer der Bank of London, wurde bei den ersten Ehrungen aus Anlass des Geburtstags Seiner Majestät König Charles III. zum Commander of the Most Excellent... ► Artikel lesen | |
| 17.06.23 | Roch Inc.: Roch Unveils World's First Universal Dog Friendly Standard and Certification Process for Hospitality, Leisure and Retail Industries | 998 | Business Wire | Roch, a dog friendly startup named after St. Roch, the patron saint of dogs, today announced the launch of The Roch Standard, the world's first universal dog friendly standard certification process... ► Artikel lesen | |
| 17.06.23 | Takeda Pharmaceutical Company Limited: Takeda und HUTCHMED melden Veröffentlichung der Ergebnisse der Phase-3-Studie FRESCO-2 in The Lancet | 1.011 | Business Wire | Veröffentlichung zeigt in der Studie FRESCO-2 für die Behandlung mit Fruquintinib nachgewiesene Senkung des Sterberisikos um 34 beim vorbehandelten metastasierten Darmkrebs (HR 0,66)
Die Daten dienen... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 5.679 |
| SUPER MICRO COMPUTER | 3.537 |
| BYD | 3.244 |
| BAYER | 3.160 |
| NEL | 2.703 |
| APPLE | 2.488 |
| NVIDIA | 2.421 |
| DEUTSCHE BANK | 2.285 |
| TUI | 2.241 |
| TESLA | 1.961 |
| MERCEDES-BENZ | 1.638 |
| PLUG POWER | 1.590 |
| AMAZON | 1.528 |
| VOLKSWAGEN | 1.468 |
| COMMERZBANK | 1.403 |
| RHEINMETALL | 1.319 |
| RWE | 1.305 |
| AIXTRON SE | 1.288 |
| NOVO NORDISK | 1.261 |
| DEUTSCHE LUFTHANSA | 1.232 |
| RENK GROUP | 1.216 |
| PAYPAL | 1.099 |
| BASF | 1.080 |
| SIEMENS ENERGY | 1.067 |
| PFIZER | 1.059 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
